Fibrinogen and Fibrin Degradation Products: Their Differentiation^[*]

• References

• 1 Astrup T. 1966; Tissue activators of plasminogen. Federation Proceedings 25: 42.
• 2 Astrup T. 1973; Blood coagulation and fibrinolysis: an ubiquitous defense mechanism of multiple regulated pathways. Thrombosis Diathesis Haemorrhagica, Supplement 54: 83.
• 3 Catanzaro A, and Edgington T. S. 1974; The in vivo behavior of the terminal derivatives of fibrinogen and fibrin cleaved by plasmin. Journal of Laboratory and Clinical Medicine 83: 458.
• 4 Dudek G. A, Kloczewiak M, Budzynski A. Z, Latallo Z. S, and Kopec M. 1970; Characterization and comparison of macromolecular end products of fibrinogen and fibrin proteolysis by plasmin. Biochimica et Biophysica Acta 214: 44.
• 5 Edgington T. S, and Plow E. F. 1973; a Coupling of the coagulation and fibrinolytic systems approached through immunologic discrimination between fibrin and fibrinogen cleavage fragments. Thrombosis et Diathesis Haemorrhagica, Supplement 54: 211.
• 6 Edgington T. S, and Plow E. F. 1975; Conformational and structural modulation of the N-terminal regions of fibrinogen and fibrin associated with plasmin cleavage. Journal of Biological Chemistry 250: 3393.
• 7 Kaplan A. P, and Austen K. F. 1972; The fibrinolytic pathway of human plasma. Isolation and characterization of the plasminogen proactivation. Journal of Experimental Medicine 136: 1378.
• 8 Kowalski E. 1968; Fibrinogen derivatives and their biologic activities. Seminars in Hematology 5: 45.
• 9 Marder V. J, and Budzynski A. Z. 1974; The structure of the fibrinogen degradation products. Progress in Hemostasis and Thrombosis 2: 141.
• 10 Plow E, and Edgington T. S. 1972; Molecular events responsible for modulation of neoantigenic expression: The cleavage-associated neoantigen of fibrinogen. Proceedings of the National Academy of Sciences U.S.A 69: 208.
• 11 Plow E. F, and Edgington T. S. 1973; a Immunobiology of fibrinogen. Emergence of neoantigenic expressions during physiologic cleavage in vitro and in vivo. Journal of Clinical Investigation 52: 273.
• 12 Plow E. F, and Edgington T. S. 1973; b Discriminating neoantigenic differences between fibrinogen and fibrin derivatives. Proceedings of the National Academy of Sciences U.S.A 70: 1169.
• 13 Plow E. F, and Edgington T. S. 1975; a An alternative pathway for fibrinolysis. I. The cleavage of fibrinogen by leukocyte proteases at physiologic pH. Journal of Clinical Investigation 56: 30.
• 14 Plow E. F, and Edgington T. S. 1975; b A cleavage associated neoantigenic marker for a gamma chain site in the N-terminal aspect of the fibrinogen molecule. Journal of Biological Chemistry 250: 3386.
• 15 Reddy K. N. N, and Markus G. 1972; Mechanism of activation of plasminogen by streptokinase. Presence of active center in streptokinase-plasminogen complex. Journal of Biological Chemistry 247: 1683.
• 16 Rifkin D. B, Loeb J. N, Moore G, and Reich E. 1974; Properties of plasminogen activators formed by neoplastic human cell cultures. Journal of Experimental Medicine 139: 1317.